anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
== Economy == Bophuthatswana was the richest of the TBVC-states as it had platinum mines, which accounted for two-thirds of the total platinum production in the Western world. It was also rich in asbestos, granite, vanadium, chromium and manganese. Additional revenues came from the Sun City casino, which was a day trip from Johannesburg and Pretoria, where gambling was illegal under the National Party government, as it was throughout all of South Africa. Bophuthatswana had a relatively capitalist free market economy, as seen by the government's drive for infrastructure development, foreign direct investments and virtually no regulatory barriers to starting and running a business. Initially, its economy was driven by agriculture then later by mining, hospitality and banking. Bophuthatswana also issued bearer development bonds. The so-called "Bop Bonds" were redeemed by the government of the North West province from 1995 to 1997, and are now worthless as financial instruments. However, bonds in excellent condition are considered collectible. Bonds issued in 1988 and 1989, in R10 and R20 denominations, currently trade at 10–25% of original face value.
== Medical complications and limitations == The Chinese study Breast Augmentation by Autologous Fat-injection Grafting: Management and Clinical analysis of Complications (2009) reported a reduced incidence of medical complications with strict control of the rate of injection (cm3/min) of the volume of breast-filler by injecting the fat-grafts in even layers within the breast-tissue matrix. The small (2-mm.) incision and blunt-cannula injections reduce the possibility of damaging the underlying structures of the breast (milk ducts, blood vessels, nerves). Injected fat-tissue grafts that do not establish an adequate blood supply can undergo necrosis from lack of oxygen and result in oil cysts that will become calcified. The medical complications (sclerotic lesions, and breast disease) occurred to the 17-patient group were identified and located with X-ray computed tomography and MRI visualizations of the breast tissues. The sclerotic lesion was excised and the liquefied fat was evacuated; the excised samples indicated biological changes in the intramammary fat grafts, such as fat necrosis, fat calcification, fat hyalinization, and fibroplasia.
=== Treating avascular necrosis === When treating avascular necrosis of the bone in people with sickle cell disease, treatment aims to reduce or stop the pain and maintain joint mobility. Treatment options include resting the joint, physical therapy, pain-relief medicine, joint-replacement surgery, or bone grafting.
His form in the first half of the year before his injuries was praised within the industry, with Herald Sun journalist, Sam Landsberger, claiming he was in All-Australian form and he signed a three-year contract with the club, tying him to the club until the end of the 2017 season. He played nineteen matches for the season and finished fourth in the best and fairest count for the second consecutive season. Hibberd played every match for the 2015 season apart from the final round match against Collingwood due to a knee injury. After strong seasons in 2013 and 2014, he had a dip in form after spending more time in the midfield. Despite a drop in form, he managed a top-ten finish in the best and fairest, placing eighth and he was named in Essendon's best players six times during the season by AFL Media.
is known as the kinematic viscosity. In this expression for Reynolds number, the characteristic length D is taken to be the hydraulic diameter of the pipe, which, for a cylindrical pipe flowing full, equals the inside diameter. In Figures 1 and 2 of friction factor versus Reynolds number, the regime Re < 2000 demonstrates laminar flow; the friction factor is well represented by the above equation. In effect, the friction loss in the laminar regime is more accurately characterized as being proportional to flow velocity, rather than proportional to the square of that velocity: one could regard the Darcy–Weisbach equation as not truly applicable in the laminar flow regime. In laminar flow, friction loss arises from the transfer of momentum from the fluid in the center of the flow to the pipe wall via the viscosity of the fluid; no vortices are present in the flow. Note that the friction loss is insensitive to the pipe roughness height ε: the flow velocity in the neighborhood of the pipe wall is zero.
Sources: en.wikipedia.org
The Golan Heights holds significance for Christians and has been a destination for pilgrims due to biblical accounts of Jesus's visitation. This includes Confession of Peter, which took place in the city of Banias (Caesarea Philippi at the time). Following the Roman Empire's recognition of Christianity, several churches and monasteries were built in the area, and numerous Christian archaeological sites remain in the Golan, such as the Kursi and Deir Qeruh, and several ruins in Banias. Christians inhabited most villages and towns mixed with Druze in the Golan, such as Jubata ez-Zeit, Zarura, 'Ayn Fit, Haspin, Fiq, Quneitra, Ain al-Shaara, Hinah, and Arnah, in addition to Majdal Shams and Ein Qiniyye, where Christians constituted two-thirds of the population in the 19th century. These Christians were divided into several denominations, including Greek Orthodox, Maronites, Roman Catholics, and Protestants. Some Druze communities were established in the Golan during the 17th and 18th centuries. During the French Mandate period, there was a significant migration of Christians from villages to the city of Quneitra, forming the second largest population group there after the Circassians. Majdal Shams played a significant role in the Great Syrian Revolt of 1925–1927. In October 1925, a few months after Syrian Druze had begun fighting French forces in the nearby province of Jabal al-Duruz, a group of the town's Druze residents looted local Christian property.
=== Critical Path Initiative === The Critical Path Initiative is the FDA's effort to stimulate and facilitate a national effort to modernize the sciences through which FDA-regulated products are developed, evaluated, and manufactured. The Initiative was launched in March 2004, with the release of a report entitled Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products.
=== Tacticity === In polystyrene, tacticity describes the extent to which the phenyl group is uniformly aligned (arranged at one side) in the polymer chain. Tacticity has a strong effect on the properties of the plastic. Standard polystyrene is atactic. The diastereomer where all of the phenyl groups are on the same side is called isotactic polystyrene, which is not produced commercially.
Langer–Giedion syndrome is a very rare genetic disorder caused by a deletion of chromosomal material. Diagnosis is usually made at birth or in early childhood. The features associated with this condition include mild to moderate learning difficulties, short stature, unique facial features, small head and skeletal abnormalities including bony growths projecting from the surfaces of bones.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.